Exagen Inc. Files 8-K on Financials and Operations
Ticker: XGN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1274737
| Field | Detail |
|---|---|
| Company | Exagen Inc. (XGN) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, filing
TL;DR
EXAGEN filed an 8-K on Jan 12, 2025, covering financials & other events. Check it out.
AI Summary
Exagen Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes financial statements and exhibits. The company, previously known as Exagen Diagnostics Inc., is incorporated in Delaware and headquartered in Vista, California.
Why It Matters
This filing provides investors with an update on Exagen Inc.'s financial performance and significant business events, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial and operational information, not indicating any immediate or significant negative developments.
Key Players & Entities
- EXAGEN INC. (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- January 13, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Vista, CA (location) — Principal executive offices address
- Exagen Diagnostics Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing by Exagen Inc.?
The primary purpose of this 8-K filing is to report on Exagen Inc.'s results of operations and financial condition, as well as other events, and to include financial statements and exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 12, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed with the SEC on January 13, 2025.
What is Exagen Inc.'s state of incorporation?
Exagen Inc. is incorporated in Delaware.
What was Exagen Inc.'s former company name?
Exagen Inc.'s former company name was Exagen Diagnostics Inc.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2025-01-13 08:00:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share XGN The Nasdaq Global Mar
Filing Documents
- exdx-20250112.htm (8-K) — 31KB
- pressrelease-2024selectpre.htm (EX-99.1) — 34KB
- imagea.jpg (GRAPHIC) — 4KB
- 0001274737-25-000003.txt ( ) — 199KB
- exdx-20250112.xsd (EX-101.SCH) — 2KB
- exdx-20250112_lab.xml (EX-101.LAB) — 21KB
- exdx-20250112_pre.xml (EX-101.PRE) — 12KB
- exdx-20250112_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 12, 2025, Exagen Inc. (the "Company") announced in a press release (the "Press Release") certain select preliminary unaudited financial information and results of operations for the three months and year ended December 31, 2024, based on currently available information. A copy of the Press Release issued by the Company is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company's financial closing procedures with respect to the select preliminary unaudited financial information and results of operations provided in the Press Release are not yet complete. These procedures often result in changes to accounts. As a result, the Company's final results may vary from the preliminary results and information presented in the Press Release. The Company undertakes no obligation to update or supplement the information and presented in the Press Release until it releases its financial statements for the three months and year ended December 31, 2024. The select preliminary unaudited financial information and results of operations included in this Current Report on Form 8-K and in the Press Release have been prepared by, and are the responsibility of, the Company. BDO USA, P.C. ("BDO") has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the select preliminary unaudited financial information and results of operations included in the Press Release and this Current Report on Form 8-K. Accordingly, BDO does not express an opinion or any other form of assurance with respect to this information. The information provided in this Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, excep
01 Other Events
Item 8.01 Other Events. The following information contained in the Press Release is deemed "filed" for purposes of Section 18 of the Exchange Act and deemed incorporated by reference into this Item 8.01: The information included under the headings "Preliminary Unaudited Select Financial Results," "Cautionary Note Regarding Select Preliminary Unaudited Financial Results," "Use of Unaudited Non-GAAP Financial Measures," " Reconciliation of Non-GAAP Financial Measures (UNAUDITED)" and "Forward Looking Statements."
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 12 , 202 5 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EXAGEN INC. Date: January 13, 2025 By: /s/ Jeffrey G. Black Jeffrey G. Black Chief Financial Officer